Zobrazeno 1 - 10
of 24
pro vyhledávání: '"Noora Sjöstedt"'
Autor:
William A. Murphy, Anna Mae Diehl, Matthew Shane Loop, Dong Fu, Cynthia D. Guy, Manal F. Abdelmalek, Georgia Sofia Karachaliou, Noora Sjöstedt, Sibylle Neuhoff, Paavo Honkakoski, Kim L. R. Brouwer
Publikováno v:
Hepatology Communications, Vol 8, Iss 3 (2024)
Background:. NAFLD is highly prevalent with limited treatment options. Bile acids (BAs) increase in the systemic circulation and liver during NAFLD progression. Changes in plasma membrane localization and zonal distribution of BA transporters can inf
Externí odkaz:
https://doaj.org/article/aac573e3c0734319af4532863a1f9a55
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2022)
Glucuronidation and sulfation are the most typical phase II metabolic reactions of drugs. The resulting glucuronide and sulfate conjugates are generally considered inactive and safe. They may, however, be the most prominent drug-related material in t
Externí odkaz:
https://doaj.org/article/38e28bc518434792a428be39698c4846
Publikováno v:
PLoS ONE, Vol 11, Iss 10, p e0163886 (2016)
The ABC transporters multidrug resistance associated protein 2 (MRP2) and breast cancer resistance protein (BCRP) are of interest in drug development, since they affect the pharmacokinetics of several drugs. Membrane vesicle transport assays are wide
Externí odkaz:
https://doaj.org/article/4defbdf4b0f74fb485b8b9331abc795a
Autor:
Johanna Tuunainen, Noora Sjöstedt, Mikko Vahteristo, Juha Ellmén, Mikko Kuoppamäki, Juha Rouru, Marjo Yliperttula
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics. 48:23-34
The treatment of Parkinson's disease (PD) is still symptomatic since disease-modifying treatments for PD are not available. Oral levodopa is the gold standard for the treatment of PD motor symptoms. However, incomplete and fluctuating plasma exposure
Autor:
William A. Murphy, Jeffry Adiwidjaja, Noora Sjöstedt, Kyunghee Yang, James J. Beaudoin, Jessica Spires, Scott Q. Siler, Sibylle Neuhoff, Kim L.R. Brouwer
Publikováno v:
Clinical Pharmacology & Therapeutics. 113:275-297
Nonalcoholic fatty liver disease (NAFLD), representing a clinical spectrum ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH), is rapidly evolving into a global pandemic. Patients with NAFLD are burdened with high rat
Drug-drug interactions (DDIs) are a major concern for the safe use of medications. Breast cancer resistance protein (BCRP) is a clinically relevant ATP-binding cassette (ABC) transporter for drug disposition. Inhibition of BCRP increases the plasma c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c6dc0e0cecc4dc90f8e84fb864943f3
http://hdl.handle.net/10138/355258
http://hdl.handle.net/10138/355258
Publikováno v:
Drug Transporters. :257-282
Autor:
Kim L. R. Brouwer, Paavo Honkakoski, Melina M. Malinen, Peter W. Swaan, Tuomo Laitinen, Henry Ho, William A. Murphy, James J. Beaudoin, Noora Sjöstedt
Publikováno v:
Molecular Pharmacology. 100:599-608
Organic solute transporter α/β (OSTα/β) is a bidirectional bile acid transporter localized on the basolateral membrane of hepatic, intestinal, and renal epithelial cells. OSTα/β plays a critical role in intestinal bile acid reabsorption and is
Autor:
Kim L.R. Brouwer, Raymond Evers, Elizabeth Hayden, Shuiying Hu, Cindy Yanfei Li, Henriette E. Meyer zu Schwabedissen, Sibylle Neuhoff, Stefan Oswald, Micheline Piquette‐Miller, Chitra Saran, Noora Sjöstedt, Jason A. Sprowl, Simone H. Stahl, Wei Yue
Publikováno v:
Clinical pharmacology and therapeutics. 112(3)
Membrane transport proteins are involved in the absorption, disposition, efficacy, and/or toxicity of many drugs. Numerous mechanisms (e.g., nuclear receptors, epigenetic gene regulation, microRNAs, alternative splicing, post-translational modificati
Publikováno v:
Toxicol Sci
Organic solute transporter (OST) α/β is a key bile acid transporter expressed in various organs, including the liver under cholestatic conditions. However, little is known about the involvement of OSTα/β in bile acid-mediated drug-induced liver i